Frequently Asked Questions

What is the difference between PamGene’s and other types of biomarkers?

Biomarker assessment such as gene or mutation detection (DNA), gene expression (RNA) or protein presence, provides diagnostic and prognostic information. PamGene directly assesses protein (kinase) activity and the effect of a drug (kinase inhibitor) on this activity, increasing the chances of successfully predicting the outcome of the chosen therapy.

What will Matching Medicines™ ultimately achieve?

PamGene aims to provide medical oncologists with valuable data that predicts an individual’s response to a specific drug prior to treatment. This guides the selection of likely responders to a specific drug and avoids non-responders experiencing unnecessary side effects and lost time.

What is the PamInDx?

This is an abbreviation of PamGene Index. This patient:drug response data provides a patient profile which aims to provide valuable predictive information to facilitate the matching of a medicine to a specific patient prior to drug administration. See our Application Note.

Who do you work with?

PamGene works in collaboration with academics, medical and pharmaceutical researchers, assessing drugs in development and those already marketed.

What kind of cells or tissues can you test for the action of a drug on kinase activity?

Cells and tissues from preclinical model systems and from patients can be used.


More FAQ's are available for PamCloud users here.